Last reviewed · How we verify
Sulphonylurea dose-up
At a glance
| Generic name | Sulphonylurea dose-up |
|---|---|
| Also known as | Amaryl |
| Sponsor | Seoul National University Bundang Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Oral Glibenclamide in Preterm Infants With Hyperglycaemia (GALOP) (PHASE2)
- Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (PHASE1)
- Screening and Molecular Diagnosis-based Individualized Precision Management of Monogenic Diabetes (NA)
- Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM (PHASE4)
- METFORMIN FOR ATRIAL FIBRILLATION (PHASE2)
- Effect of Empagliflozin on Body Composition and Ketones (PHASE4)
- Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004) (PHASE3)
- Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sulphonylurea dose-up CI brief — competitive landscape report
- Sulphonylurea dose-up updates RSS · CI watch RSS
- Seoul National University Bundang Hospital portfolio CI